Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$80.74 - $97.7 $2.42 Million - $2.93 Million
-30,000 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$85.07 - $109.69 $1.79 Million - $2.3 Million
-21,000 Reduced 41.18%
30,000 $2.69 Million
Q2 2020

Feb 12, 2021

BUY
$74.18 - $108.93 $3.75 Million - $5.5 Million
50,490 Added 9900.0%
51,000 $5.3 Million
Q2 2020

Aug 14, 2020

BUY
$74.18 - $108.93 $37,831 - $55,554
510 New
510 $31,000
Q3 2019

Nov 14, 2019

SELL
$72.82 - $86.52 $7.28 Million - $8.65 Million
-100,000 Closed
0 $0
Q2 2019

Feb 12, 2021

BUY
$73.52 - $88.7 $7.28 Million - $8.78 Million
99,000 Added 9900.0%
100,000 $8.5 Million
Q2 2019

Aug 14, 2019

SELL
$73.52 - $88.7 $15.4 Million - $18.5 Million
-209,000 Reduced 99.52%
1,000 $173,000
Q4 2018

Feb 11, 2021

BUY
$58.5 - $69.94 $12.2 Million - $14.5 Million
207,900 Added 9900.0%
210,000 $13.4 Million
Q4 2018

Feb 14, 2019

SELL
$58.5 - $69.94 $462,150 - $552,526
-7,900 Reduced 79.0%
2,100 $26,000
Q3 2018

Feb 11, 2021

BUY
$61.75 - $74.23 $611,325 - $734,877
9,900 Added 9900.0%
10,000 $691,000
Q3 2018

Nov 14, 2018

SELL
$61.75 - $74.23 $611,325 - $734,877
-9,900 Reduced 99.0%
100 $45,000
Q2 2018

Feb 11, 2021

BUY
$60.85 - $83.98 $602,415 - $831,402
9,900 Added 9900.0%
10,000 $670,000
Q2 2018

Aug 14, 2018

SELL
$60.85 - $83.98 $1.21 Million - $1.67 Million
-19,900 Reduced 99.5%
100 $61,000
Q1 2018

Feb 11, 2021

BUY
$83.06 - $100.98 $1.64 Million - $2 Million
19,800 Added 9900.0%
20,000 $1.67 Million
Q1 2018

May 14, 2018

SELL
$83.06 - $100.98 $1.64 Million - $2 Million
-19,800 Reduced 99.0%
200 $0
Q4 2017

Feb 11, 2021

SELL
$93.56 - $116.6 $2.81 Million - $3.5 Million
-30,000 Reduced 60.0%
20,000 $1.89 Million
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $5.46 Million - $6.91 Million
50,000
50,000 $630 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Pura Vida Investments, LLC Portfolio

Follow Pura Vida Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pura Vida Investments, LLC with notifications on news.